Encyclopedia of Clinical Neuropsychology

Living Edition
| Editors: Jeffrey Kreutzer, John DeLuca, Bruce Caplan

Novel Oral Anticoagulants

  • Elliot Roth
Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-56782-2_9277-1



Novel oral anticoagulants constitute a new class of mediations that have recently gained widespread use. These medications include apixaban (Eliquis®), dabigatran (Pradaxa®), edoxaban (Savaysa®), and rivaroxaban (Xarelto®).

Current Knowledge

These medications use a different mechanism of action compared to the older anticoagulant medications. They work by inhibiting thrombin and factor Xa, which are two of the “clotting factors” that contribute to the formation of blood clots. Demonstration of the effectiveness of these new medications in the prevention and treatment of deep vein thrombosis, coronary disease, and stroke constitutes a major focus of current research.

The newer anticoagulants are considered to have similar effectiveness to the more classic anticoagulants such as warfarin, but the new medications offer the advantages of fixed dosing, minimal food and drug interactions, and minimal...

This is a preview of subscription content, log in to check access.


  1. van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014). Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 12, 320–328.CrossRefGoogle Scholar
  2. Yeh, C. H., Hogg, K., & Weitz, J. I. (2015). Overview of the new oral anticoagulants: Opportunities and challenges. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 1056–1065.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Feinberg School of Medicine, Physical Medicine and RehabilitationNorthwestern UniversityChicagoUSA